Latin America and the Caribbean has become a focal point in the global rise of multidrug-resistant Enterobacterales, with Klebsiella pneumoniae and Escherichia coli at the centre of the problem. The article argues that the region’s experience is not simply a matter of resistant bacteria appearing in isolation, but of a wider ecological and institutional failure: fragmented care, uneven access to antibiotics, weak diagnostics and intense cross-border movement have created ideal conditions for resistance to spread.

Recent surveillance data cited in the article suggest that carbapenem resistance in K. pneumoniae has reached alarming levels across the region, with some countries seeing rates as high as 30 per cent and some hospitals in Colombia reportedly approaching 50 per cent. The pattern is becoming more complex as multiple carbapenemase types circulate at once, including KPC, metallo-β-lactamases and OXA-48-like enzymes. The article also points to rising resistance to ceftazidime-avibactam, a development that may reflect both the spread of metallo-β-lactamase producers and the emergence of altered KPC variants.

That genetic complexity is reinforced by the movement of high-risk clones such as ST258, ST11, ST307 and ST147, which help resistance traits travel between species and institutions. In practice, this makes outbreaks harder to detect and contain, especially where access to rapid molecular testing remains limited. The result, the article says, is a diagnostic blind spot that allows parallel mini-epidemics to unfold within the same hospital.

The hospital environment sits at the centre of the crisis. The CDC’s guidance on carbapenem-resistant Enterobacterales stresses contact precautions, hand hygiene, environmental cleaning and close coordination with public health authorities, while a CDC review in acute care settings reinforces the need for aggressive infection control and reliable laboratory detection. A systematic review in PMC similarly highlights surveillance cultures, patient isolation or cohorting, and stronger training for staff. Those measures echo the article’s argument that the spread of resistance is driven as much by weak infection prevention as by microbiology.

The clinical consequences are severe. The article cites high mortality in bloodstream infections caused by carbapenem-resistant Gram-negative bacteria and notes that newer options such as aztreonam-avibactam have shown strong activity in studies, yet remain largely unavailable in Latin America and the Caribbean. That leaves clinicians relying on older, more toxic drugs such as polymyxins. The author calls for a broader response: stronger regional surveillance, better stewardship, improved hospital ecology and even a pooled purchasing mechanism for reserve antibiotics, modelled partly on PAHO’s vaccine revolving fund and subscription-style reimbursement approaches used elsewhere.

Source Reference Map

Inspired by headline at: [1]

Sources by paragraph:

Source: Noah Wire Services